View Financial HealthRange Impact 배당 및 자사주 매입배당 기준 점검 0/6Range Impact 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률-4.8%자사주 매입 수익률총 주주 수익률-4.8%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공지 • Sep 25Range Impact, Inc. announced that it has received $0.55 million in funding from Tower Iv LLCRange Impact, Inc. entered into securities purchase agreements with Edward Feighan, the Chairman of the Board of Directors of the Company, Michael Cavanaugh, a director and Chief Executive Officer of the Company, and Tower IV, LLC, an existing shareholder of the Company on September 23, 2025. The company has issued 3,666,667 shares at a price of $0.15 per share for gross proceeds $550,000.05. Messrs. Feighan and Cavanaugh each invested $100,000 in the Shares and Tower IV, LLC invested $350,000. The transaction was closed on September 23, 2025.공지 • Oct 03Placer Biosciences, Inc. acquired Graphium Biosciences, Inc. from Range Impact, Inc. (OTCPK:RNGE).Placer Biosciences, Inc. acquired Graphium Biosciences, Inc. from Range Impact, Inc. (OTCPK:RNGE) on September 30, 2024. A cash consideration will be paid by Placer Biosciences, Inc. As part of consideration, an undisclosed value is paid towards None of Graphium Biosciences, Inc. The consideration consists of (i) a warrant exchangeable into 1,000 shares of the common stock of the Purchaser, exercisable at $0.01 per share, expiring September 30, 2034, subject to certain anti-dilution adjustments; (ii) de minimis cash consideration; and (iii) 50% of any equipment sale proceeds realized by Purchaser during the 12-month period following the closing. The Stock Purchase Agreement contains terms, conditions, covenants, indemnification provisions, and representations and warranties from each of the respective parties that are customary and typical for a transaction of this nature. After a close review and examination of the status of both corporate strategies and the current market environment, the Company’s Board of Directors determined that it is in the shareholders’ best interests to separate these two distinct businesses by divesting Graphium. UB Greensfelder LLP acted as legal advisor to Range. Thompson Coburn LLP acted as legal advisor to Placer. Placer Biosciences, Inc. completed the acquisition of Graphium Biosciences, Inc. from Range Impact, Inc. (OTCPK:RNGE) on September 30, 2024.공지 • Jun 21Continental Heritage Holding Company, Llc acquired an unknown minority stake in Range Impact, Inc. (OTCPK:RNGE) for $1 million.Continental Heritage Holding Company, Llc acquired an unknown minority stake in Range Impact, Inc. (OTCPK:RNGE) for $1 million on June 17, 2024. A cash consideration valued at $0.27 per share will be paid by Continental Heritage Holding Company, Llc for the acquisition of 3,703,704 shares of the Company’s common stock. Continental Heritage Holding Company, Llc completed the acquisition of an unknown minority stake in Range Impact, Inc. (OTCPK:RNGE) on June 17, 2024.공지 • Apr 28+ 1 more updateRange Impact, Inc. Announces Chief Financial Officer ChangesRange Impact, Inc. (Range Impact) announced the transition of Richard McKilligan, Chief Financial Officer from Range Impact to Graphium Biosciences, Inc. (Graphium), a wholly owned subsidiary of Range Impact, in connection with a proposed divestiture and recapitalization of Graphium. Additionally, Range Impact has promoted Patricia Missal from her role as Corporate Controller to Chief Financial Officer. Mr. McKilligan joined the company in 2012 and held several management positions, including Controller, Counsel, and Chief Financial Officer. In connection with this expanded business strategy, all the company’s legacy drug development assets (for which Mr. McKilligan served in key leadership roles over the past decade) were transferred into Graphium in preparation for a future strategic transaction. Ms. Missal, age 55, has served as Controller of the Company since January 2023. Ms. Missal previously served as the Chief Financial Officer of Lux Global Label Company from August 2019 to February 2020, and then again from June 2021 to December 2022. She also served as Chief Financial Officer of Thirty-One Gifts, LLC from December 2019 to June 2021, and as Chief Financial Officer of Aero Communications, Inc. from September 2011 to June 2019. Ms. Missal, a CPA, received her BSBA in Accounting from Ashland University and her MBA from Cleveland State University.공지 • Dec 22Range Impact, Inc. announced that it has received $1.7 million in fundingRange Impact, Inc. announced that it has entered into securities purchase agreements with each of the purchasers to issue 11,333,336 shares at an issue price of $0.15 per share for the gross proceeds of $1,700,000.4 on December 21, 2023. The sale of the Shares was exempt from the registration requirements of the Securities Act as transactions by an issuer not involved in any public offering under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D promulgated under the Securities Act (“Regulation D”). The Company made this determination based on the representations of the Purchasers in the Purchase Agreements, including, but not limited to, that each of them is an “accredited investor” within the meaning of Rule 501 of Regulation D and each of them had access to full and complete information about the Company and its investment.공지 • Sep 07Malachite Innovations, Inc. (OTCPK:MLCT) acquired Collins Building & Contracting, Inc. from Roger L. Collins, Jr. for $5.035 million.Malachite Innovations, Inc. (OTCPK:MLCT) acquired Collins Building & Contracting, Inc. from Roger L. Collins, Jr. for $5.035 million on August 31, 2023. The consideration comprised of $1.0 million of cash, a $2.0 million seller note collateralized by the acquired real estate and quarry infrastructure, and a separate $2.035 million seller note collateralized by the acquired equipment. Roger Collins will serve as Senior Vice President of Sales of Range Environmental Resources, Inc., a wholly-owned subsidiary of Malachite. Howard Groedel of Ulmer & Berne acted as legal advisor to Malachite Innovations, Inc. Thomas Spears of Daniels Law Firm, PLLC acted as legal advisor to Roger L. Collins, Jr. Malachite Innovations, Inc. (OTCPK:MLCT) acquired Collins Building & Contracting, Inc. on August 31, 2023.공지 • Aug 17Malachite Innovations, Inc. announced delayed 10-Q filingOn 08/16/2022, Malachite Innovations, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공지 • Aug 21Vitality Biopharma, Inc. announced that it expects to receive $5 million in fundingVitality Biopharma, Inc. announced that it has entered into a securities purchase agreement with a institutional investor for private placement of common shares for gross proceeds of up to $5,000,000 on August 19, 2021. The company will issue shares in tranches of up to $250,000 until the financing arrangement expires on December 31, 2022. The share price is equal to 85% of the lowest daily volume weighted average price during the 5 trading days prior the 3rd business day following its submission of the purchase notice. The company will also issue warrants at a price equal to 115% of the lowest daily volume weighted average price expires on the five-year anniversary of the date of issuance.공지 • Sep 26Vitality Biopharma, Inc. Elects Brandon Zipp as Chief Science OfficerOn September 24, 2020, the Board of Directors of Vitality Biopharma, Inc. elected Dr. Brandon Zipp as Chief Science Officer.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 RNGE 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: RNGE 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Range Impact 배당 수익률 vs 시장RNGE의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (RNGE)n/a시장 하위 25% (US)1.4%시장 상위 25% (US)4.3%업계 평균 (Commercial Services)1.3%분석가 예측 (RNGE) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 RNGE 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 RNGE 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 RNGE 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: RNGE 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YUS 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/13 23:51종가2026/05/13 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Range Impact, Inc.는 1명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Amit DayalH.C. Wainwright & Co.
공지 • Sep 25Range Impact, Inc. announced that it has received $0.55 million in funding from Tower Iv LLCRange Impact, Inc. entered into securities purchase agreements with Edward Feighan, the Chairman of the Board of Directors of the Company, Michael Cavanaugh, a director and Chief Executive Officer of the Company, and Tower IV, LLC, an existing shareholder of the Company on September 23, 2025. The company has issued 3,666,667 shares at a price of $0.15 per share for gross proceeds $550,000.05. Messrs. Feighan and Cavanaugh each invested $100,000 in the Shares and Tower IV, LLC invested $350,000. The transaction was closed on September 23, 2025.
공지 • Oct 03Placer Biosciences, Inc. acquired Graphium Biosciences, Inc. from Range Impact, Inc. (OTCPK:RNGE).Placer Biosciences, Inc. acquired Graphium Biosciences, Inc. from Range Impact, Inc. (OTCPK:RNGE) on September 30, 2024. A cash consideration will be paid by Placer Biosciences, Inc. As part of consideration, an undisclosed value is paid towards None of Graphium Biosciences, Inc. The consideration consists of (i) a warrant exchangeable into 1,000 shares of the common stock of the Purchaser, exercisable at $0.01 per share, expiring September 30, 2034, subject to certain anti-dilution adjustments; (ii) de minimis cash consideration; and (iii) 50% of any equipment sale proceeds realized by Purchaser during the 12-month period following the closing. The Stock Purchase Agreement contains terms, conditions, covenants, indemnification provisions, and representations and warranties from each of the respective parties that are customary and typical for a transaction of this nature. After a close review and examination of the status of both corporate strategies and the current market environment, the Company’s Board of Directors determined that it is in the shareholders’ best interests to separate these two distinct businesses by divesting Graphium. UB Greensfelder LLP acted as legal advisor to Range. Thompson Coburn LLP acted as legal advisor to Placer. Placer Biosciences, Inc. completed the acquisition of Graphium Biosciences, Inc. from Range Impact, Inc. (OTCPK:RNGE) on September 30, 2024.
공지 • Jun 21Continental Heritage Holding Company, Llc acquired an unknown minority stake in Range Impact, Inc. (OTCPK:RNGE) for $1 million.Continental Heritage Holding Company, Llc acquired an unknown minority stake in Range Impact, Inc. (OTCPK:RNGE) for $1 million on June 17, 2024. A cash consideration valued at $0.27 per share will be paid by Continental Heritage Holding Company, Llc for the acquisition of 3,703,704 shares of the Company’s common stock. Continental Heritage Holding Company, Llc completed the acquisition of an unknown minority stake in Range Impact, Inc. (OTCPK:RNGE) on June 17, 2024.
공지 • Apr 28+ 1 more updateRange Impact, Inc. Announces Chief Financial Officer ChangesRange Impact, Inc. (Range Impact) announced the transition of Richard McKilligan, Chief Financial Officer from Range Impact to Graphium Biosciences, Inc. (Graphium), a wholly owned subsidiary of Range Impact, in connection with a proposed divestiture and recapitalization of Graphium. Additionally, Range Impact has promoted Patricia Missal from her role as Corporate Controller to Chief Financial Officer. Mr. McKilligan joined the company in 2012 and held several management positions, including Controller, Counsel, and Chief Financial Officer. In connection with this expanded business strategy, all the company’s legacy drug development assets (for which Mr. McKilligan served in key leadership roles over the past decade) were transferred into Graphium in preparation for a future strategic transaction. Ms. Missal, age 55, has served as Controller of the Company since January 2023. Ms. Missal previously served as the Chief Financial Officer of Lux Global Label Company from August 2019 to February 2020, and then again from June 2021 to December 2022. She also served as Chief Financial Officer of Thirty-One Gifts, LLC from December 2019 to June 2021, and as Chief Financial Officer of Aero Communications, Inc. from September 2011 to June 2019. Ms. Missal, a CPA, received her BSBA in Accounting from Ashland University and her MBA from Cleveland State University.
공지 • Dec 22Range Impact, Inc. announced that it has received $1.7 million in fundingRange Impact, Inc. announced that it has entered into securities purchase agreements with each of the purchasers to issue 11,333,336 shares at an issue price of $0.15 per share for the gross proceeds of $1,700,000.4 on December 21, 2023. The sale of the Shares was exempt from the registration requirements of the Securities Act as transactions by an issuer not involved in any public offering under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D promulgated under the Securities Act (“Regulation D”). The Company made this determination based on the representations of the Purchasers in the Purchase Agreements, including, but not limited to, that each of them is an “accredited investor” within the meaning of Rule 501 of Regulation D and each of them had access to full and complete information about the Company and its investment.
공지 • Sep 07Malachite Innovations, Inc. (OTCPK:MLCT) acquired Collins Building & Contracting, Inc. from Roger L. Collins, Jr. for $5.035 million.Malachite Innovations, Inc. (OTCPK:MLCT) acquired Collins Building & Contracting, Inc. from Roger L. Collins, Jr. for $5.035 million on August 31, 2023. The consideration comprised of $1.0 million of cash, a $2.0 million seller note collateralized by the acquired real estate and quarry infrastructure, and a separate $2.035 million seller note collateralized by the acquired equipment. Roger Collins will serve as Senior Vice President of Sales of Range Environmental Resources, Inc., a wholly-owned subsidiary of Malachite. Howard Groedel of Ulmer & Berne acted as legal advisor to Malachite Innovations, Inc. Thomas Spears of Daniels Law Firm, PLLC acted as legal advisor to Roger L. Collins, Jr. Malachite Innovations, Inc. (OTCPK:MLCT) acquired Collins Building & Contracting, Inc. on August 31, 2023.
공지 • Aug 17Malachite Innovations, Inc. announced delayed 10-Q filingOn 08/16/2022, Malachite Innovations, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공지 • Aug 21Vitality Biopharma, Inc. announced that it expects to receive $5 million in fundingVitality Biopharma, Inc. announced that it has entered into a securities purchase agreement with a institutional investor for private placement of common shares for gross proceeds of up to $5,000,000 on August 19, 2021. The company will issue shares in tranches of up to $250,000 until the financing arrangement expires on December 31, 2022. The share price is equal to 85% of the lowest daily volume weighted average price during the 5 trading days prior the 3rd business day following its submission of the purchase notice. The company will also issue warrants at a price equal to 115% of the lowest daily volume weighted average price expires on the five-year anniversary of the date of issuance.
공지 • Sep 26Vitality Biopharma, Inc. Elects Brandon Zipp as Chief Science OfficerOn September 24, 2020, the Board of Directors of Vitality Biopharma, Inc. elected Dr. Brandon Zipp as Chief Science Officer.